Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37268 | 1.00 | CYP3A4 (1.00) | CYP3A4TSHRHPGDSMN1; SMN2MEN1 | |
| SCHEMBL3898989 | 1.00 | CYP3A4 (1.00) | CYP3A4TSHRHPGDSMN1; SMN2MEN1 | |
| Phosphine SCHEMBL28928133 | 1.00 | CYP3A4 (1.00) | CYP3A4TSHRHPGDSMN1; SMN2MEN1 | |
| SCHEMBL15695763 | 0.96 | CYP3A4 (0.91) | CYP3A4TSHRHPGDSMN1; SMN2MEN1 | |
| SCHEMBL15293625 | 0.96 | CYP3A4 (0.91) | CYP3A4TSHRHPGDSMN1; SMN2MEN1 | |
| SCHEMBL15293624 | 0.96 | CYP3A4 (0.91) | CYP3A4TSHRHPGDSMN1; SMN2MEN1 | |
| SCHEMBL116616 | 0.95 | CYP3A4 (0.91) | CYP3A4TSHRHPGDSMN1; SMN2 | |
| SCHEMBL8916348 | 0.94 | TSHR (0.88) | CYP3A4TSHRHPGDSMN1; SMN2 | |
| SCHEMBL15283502 | 0.94 | TSHR (0.88) | CYP3A4TSHRHPGDSMN1; SMN2MEN1 | |
| SCHEMBL6273415 | 0.93 | CYP3A4 (0.87) | CYP3A4TSHRHPGDSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9587130-B2 | Anti-kogation agents | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2619274-B1 | ANTI-KOGATION AGENTS | HEWLETT PACKARD DEVELOPMENT CO (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20130194364-A1 | Anti-Kogation Agents | HEWLETT-PACKARD DEVELOPEMENT COMPANY, L.P. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2619274-A1 | ANTI-KOGATION AGENTS | Hewlett-Packard Development Company, L.P. (US) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012039721-A1 | ANTI-KOGATION AGENTS | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2012-03-29 | — | — | WO | disclosed |
| EP-0965328-B1 | COSMETIC | KAO CORP (JP) | 2009-03-04 | — | — | EP | disclosed |
| US-6932975-B2 | Cosmetic composition comprising a phosphoric triester and a skin activating component | KAO CORPORATION (JP) | 2005-08-23 | — | — | US | disclosed |
| US-20050123578-A1 | Method of treating skin with a composition comprising a phosphoric triester and a skin activating component | KAO CORPORATION (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20020187166-A1 | COSMETIC COMPOSITION COMPRISING A PHOSPHORIC TRIESTER AND A SKIN ACTIVATING COMPONENT | KAO CORPORATION (JP) | 2002-12-12 | — | — | US | disclosed |
| EP-0965328-A1 | COSMETIC | Kao Corporation (JP) | 1999-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050123578-A1 | Method of treating skin with a composition comprising a phosphoric triester and a skin activating component | CUTA, PIM1, PIM2 | CYP3A4 3561/4885TSHR 1920/4885HPGD 4590/4885 |
| US-20020187166-A1 | COSMETIC COMPOSITION COMPRISING A PHOSPHORIC TRIESTER AND A SKIN ACTIVATING COMPONENT | CUTA, PIM1, PIM2 | CYP3A4 3813/4885TSHR 2181/4885HPGD 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.